9月16日,今海医疗科技(HK2225)(02225.HK)公布截至2026年6月30日止六个月未经审核中期业绩。期内收益由2025年上半年的1450万新加坡元增加至3400万新加坡元,主要来自微创手术解决方案及医疗产品和相关服务费的收益由630万新加坡元增加至2540万新加坡元。毛利由210万新加坡元增加至660万新加坡元,毛利率由14.3%上升至19.5%。期内亏损由1080万新加坡元收窄至...
Source Link9月16日,今海医疗科技(HK2225)(02225.HK)公布截至2026年6月30日止六个月未经审核中期业绩。期内收益由2025年上半年的1450万新加坡元增加至3400万新加坡元,主要来自微创手术解决方案及医疗产品和相关服务费的收益由630万新加坡元增加至2540万新加坡元。毛利由210万新加坡元增加至660万新加坡元,毛利率由14.3%上升至19.5%。期内亏损由1080万新加坡元收窄至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.